INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

INmune Bio, Inc.NASDAQ: INMB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's FY2025 gross margin of 100.0% is the highest of the 2 companies compared; the peer median is 79.4%.
  • Its year-over-year change of +0.0 pp is the highest of 2, against a peer median of -1.2 pp.
INMB Competitors Peer median
Gross Margin for INMB and competitors
Company Period LTM level YoY 3-year change
INMBINmune Bio, Inc.FY2025100.0% +0.0 pp+0.0 pp
XFORX4 Pharmaceuticals, Inc.LTM Mar 202679.4% -1.2 pp—
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
Peer median (excluding INMB) 79.4%-1.2 pp—

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue181K374K155K14K50K
Cost of Revenue00000
Gross Profit181K374K155K14K50K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development20.54M17.07M20.27M33.17M20.66M
Selling, General & Admin8.79M9.26M9.62M9.48M10.26M
Operating Expenses29.33M26.33M29.9M42.65M30.92M
Depreciation & Amortization29.15M25.95M29.74M553K84K
EBITDA(1.19M)(1.35M)(267K)(41.53M)(45.85M)
EBITDA Margin-655.8%-360.4%-172.3%-296635.7%-91698.0%
Operating Income(29.15M)(25.95M)(29.74M)(42.64M)(30.87M)
Operating Margin-16106.6%-6938.8%-19187.7%-304535.7%-61738.0%
Interest Income0000850K
Interest Expense00000
Other Income / Expenses(1.19M)(1.35M)(267K)553K(15.06M)
Income Before Tax(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Pre-Tax Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
Income Tax Expense00000
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Net Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
EPS (Basic)(1.88)(1.52)(1.67)(2.11)(1.86)
EPS (Diluted)(1.88)(1.52)(1.67)(2.11)(1.86)
Weighted Avg Shares16.13M17.93M17.98M19.94M26.59M
Weighted Avg Shares (Diluted)16.13M17.93M17.98M19.94M26.59M

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.